CClinicalTrials.gg
CompletedNCT06905665Updated Apr 1, 2025

The EFFECT of VİRTUAL REALİTY (VR) HEADSET USE on ANXİETY LEVELS DURİNG URODYNAMİC TESTİNG

An interventional study of Virtual reality group in Virtual Reality Headsets Reduce Anxiety During Urodynamic Tests, sponsored by Trabzon Kanuni Education and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Trabzon Kanuni Education and Research Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Apr 2023, registered Mar 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This randomized trial tested if VR headsets reduce anxiety during urodynamic tests. First-time adult patients (18-70) were split into VR (nature videos) and control groups, with anxiety measured before and after using standard surveys. Results will show if VR offers drug-free anxiety relief for this procedure.

Read the detailed description

This study was designed as a pre-test and post-test randomized controlled trial to determine the effect of VR headset use on anxiety levels in patients undergoing urodynamic testing. Patients scheduled for urodynamic evaluation in our clinic between April 20, 2023, and June 30, 2023, were included in the study. Participants were randomized into two groups-VR and control-using the computer-based Research Randomizer program. Ethical approval for the study was obtained from the local ethics committee (2023/17).

Inclusion Criteria:

  • Individuals aged 18-70 undergoing urodynamic testing for the first time
  • Individuals with the mental capacity to decide whether they wish to participate in the study
  • No communication difficulties

Exclusion Criteria:

  • Use of any psychiatric medication
  • Individuals with visual impairments
  • Individuals with speech disorders
  • Individuals experiencing complications during the urodynamic procedure
  • Withdrawal from the study For the VR group, the purpose of the study was explained before the procedure, and both verbal and written informed consent were obtained. Additionally, patients were provided with detailed information about how to use the headset, what to expect, and the content of the video before viewing. Data collection forms and the State-Trait Anxiety Inventory (STAI I-II) were completed using a face-to-face interview technique before the procedure.

During the urodynamic procedure, an Efnan G04EA VR Shinecon 3D headset was used. The patient was positioned appropriately on the examination table, and the VR headset was fitted onto their head with a smartphone placed inside. A thin pillow was placed under the patient's head, and efforts were made to ensure their privacy and comfort. Throughout the urodynamic procedure (approximately 30 minutes), patients watched pre-recorded 360-degree nature scenery videos via YouTube. Care was taken to exclude any visual or auditory stimuli that could influence urodynamic results (e.g., sounds of water, rivers, waterfalls, streams). Patients were informed that they could remove the headset at any time if they experienced discomfort.

For the control group, no additional interventions were applied beyond the routine procedure. Before the procedure, participants completed the Data Collection Form and the State-Trait Anxiety Inventory (STAI I-II).

The Data Collection Form included 14 questions designed to gather demographic and clinical characteristics such as gender, height, weight, age, marital status, education level, employment status, smoking and alcohol consumption, income level, presence of chronic diseases, history of previous surgeries, history of prior urodynamic testing, coping strategies used during anxiety, and prior knowledge of the urodynamic procedure, including the source of their information. In addition to these questions, the VR group was also asked whether they would prefer using a VR headset for future urodynamic procedures and whether they would recommend it to other patients.

State-Trait Anxiety Inventory (STAI I-II)

The STAI I-II was developed by Spielberger et al. in 1970 to separately measure state and trait anxiety levels. This inventory consists of two separate scales, each containing 20 items, with some questions assessing negative emotions and others evaluating positive emotions. The STAI-I measures state anxiety by asking individuals to rate their anxiety level at a specific time under specific conditions using a four-point Likert scale:

  1. = Not at all
  2. = Somewhat
  3. = Very much
  4. = Completely The total score represents the individual's state anxiety level at that moment.

The STAI-II assesses trait anxiety by evaluating how individuals generally feel, independent of their current situation. Participants rate the frequency of their anxiety using the following scale:

  1. = Almost never
  2. = Sometimes
  3. = Often
  4. = Almost always Each scale consists of 20 questions, with scores ranging from 20 to 80, where higher scores indicate higher anxiety levels.18,19 At the end of the procedure, participants in both groups completed the STAI Form I again. Pre- and post-procedure scores were compared between the two groups.
02

Conditions studied

  • Virtual Reality Headsets Reduce Anxiety During Urodynamic Tests

Browse trials for

Keywords

  • Virtual reality, urodynamics, anxiety, lower urinary tract dysfunction
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 86 is close to the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Trabzon Kanuni Education and Research Hospital is the lead sponsor of 12 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Individuals aged 18-70 undergoing urodynamic testing for the first time
  • Individuals with the mental capacity to decide whether they wish to participate in the study
  • No communication difficulties

Exclusion criteria

Exclusion Criteria:

  • Use of any psychiatric medication
  • Individuals with visual impairments
  • Individuals with speech disorders
  • Individuals experiencing complications during the urodynamic procedure
  • Withdrawal from the study
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Other
    control group

    For the control group, no additional interventions were applied beyond the routine procedure. Before the procedure, participants completed the Data Collection Form and the State-Trait Anxiety Inventory (STAI I-II). The Data Collection Form included 14 questions designed to gather demographic and clinical characteristics such as gender, height, weight, age, marital status, education level, employment status, smoking and alcohol consumption, income level, presence of chronic diseases, history of previous surgeries, history of prior urodynamic testing, coping strategies used during anxiety, and prior knowledge of the urodynamic procedure, including the source of their information

    Device: Virtual reality group

Interventions

  • DeviceVirtual reality group

    For the VR group, the purpose of the study was explained before the procedure, and both verbal and written informed consent were obtained. Additionally, patients were provided with detailed information about how to use the headset, what to expect, and the content of the video before viewing. Data collection forms and the State-Trait Anxiety Inventory (STAI I-II) were completed using a face-to-face interview technique before the procedure.During the urodynamic procedure, an Efnan G04EA VR Shinecon 3D headset was used. The patient was positioned appropriately on the examination table, and the VR headset was fitted onto their head with a smartphone placed inside. A thin pillow was placed under the patient's head, and efforts were made to ensure their privacy and comfort. Throughout the urodynamic procedure (approximately 30 minutes),

06

What researchers measure

Primary outcomes

  1. State-Trait Anxiety Inventory (STAI I-II)

    The STAI I-II was developed by Spielberger et al. in 1970 to separately measure state and trait anxiety levels. This inventory consists of two separate scales, each containing 20 items, with some questions assessing negative emotions and others evaluating positive emotions. The STAI-I measures state anxiety by asking individuals to rate their anxiety level at a specific time under specific conditions using a four-point Likert scale: 1. = Not at all 2. = Somewhat 3. = Very much 4. = Completely The total score represents the individual's state anxiety level at that moment. The STAI-II assesses trait anxiety by evaluating how individuals generally feel, independent of their current situation. Participants rate the frequency of their anxiety using the following scale: 1. = Almost never 2. = Sometimes 3. = Often 4. = Almost always Each scale consists of 20 questions, with scores ranging from 20 to 80, where higher scores indicate higher anxiety levels.

    Time frame: 1 (one) day

07

Study locations

1 site
  • Trabzon Kanuni Education and Research Hospital
    Trabzon, 38000, Turkey
08

References and documents

Individual participant data

Plan to share: No — I don't have a URL address

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06905665
Lead sponsor
Trabzon Kanuni Education and Research Hospital
Responsible party
Nurten Seyis SİBAL (NURSE, Trabzon Kanuni Education and Research Hospital) — Principal investigator
First posted
Apr 1, 2025
Start date
Apr 20, 2023
Primary completion
Jun 20, 2023
Completion
Sep 20, 2023
Last update
Apr 1, 2025

Study contacts

Nurten S SİBAL, Nurse
principal investigator · Avrasya University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion